The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Open accessAbstract
Immunotherapy has become a key therapeutic strategy in the treatment of many cancers. As a result, research efforts have been aimed at understanding mechanisms of resistance to immunotherapy and how anti-tumor immune response can be therapeutically enhanced. It has been shown that tumor cell recognition by the immune system plays a key role in effective response to T cell targeting therapies in patients. One mechanism by which tumor cells can avoid immunosurveillance is through the downregulation of Major Histocompatibility Complex I (MHC-I). Downregulation of MHC-I has been described as a mechanism of intrinsic and acquired resistance to immunotherapy in patients with cancer. Depending on the mechanism, the downregulation of MHC-I can sometimes be therapeutically restored to aid in anti-tumor immunity. In this article, we will review current research in MHC-I downregulation and its impact on immunotherapy response in patients, as well as possible strategies for therapeutic upregulation of MHC-I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 3×
“Additionally, truncating mutations of b2M were found in metastatic colon and melanoma cancers found to be resistant to the anti-PD-1 therapy, pembrolizumab (25, 49, 50).”
BackgroundClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · cited 1×
“One clinical study designed to test adoptive transfer of T-cells revealed that downregulation of HLA-C was linked with immune evasion and lack of response to treatment (46).”
BackgroundPrimary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · cited 1×
“In addition, Ptpn2, was identified through an in vivo CRISPR screen to negatively regulate the JAK/STAT and antigen presentation pathways leading to ICI resistance (89).”
BackgroundPatient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · cited 2×
“TsMHC-I associates with improved response to ICI and increased amounts of tumor infiltrating lymphocytes (44, 81, 83, 87, 90)Loss of MHC-I antigen presentation is common in cancers and allows tumors to evade immune surveillance.”
BackgroundHistone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Kaer, L. V., Ashton-Rickardt, P. G., Ploegh, H. L., & Tonegawa, S. (1992) · Cell · doi:10.1016/s0092-8674(05)80068-6 · Cited by 724
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 649
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Self-citationGenetic Mechanisms of Immune Evasion in Colorectal Cancer
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535
A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.
Perkins, N. D., Edwards, N. L., Duckett, C. S., Agranoff, A. B., Schmid, R. M., & Nabel, G. J. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06029.x · Cited by 484
Lauss, M., Donia, M., Harbst, K., Andersen, R., Mitra, S., Rosengren, F., Salim, M., Vallon-Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 470
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 464
Hastings, K., Yu, H. A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz141 · Cited by 366
Mechanisms of Cancer Resistance to Immunotherapy
Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 353
Michalek, M. T., Grant, E. P., Gramm, C., Goldberg, A. L., & Rock, K. L. (1993) · Nature · doi:10.1038/363552a0 · Cited by 321
Paul, S., Weiskopf, D., Angelo, M. A., Sidney, J., Peters, B., & Sette, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302101 · Cited by 298
Lee, J. H., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15726-7 · Cited by 288
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S. J., Church, C. D., Vandeven, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 286
Hodge, J. W., Garnett, C. T., Farsaci, B., Palena, C., Tsang, K., Ferrone, S., & Gameiro, S. R. (2013) · International Journal of Cancer · doi:10.1002/ijc.28070 · Cited by 281
NLRC5/MHC class I transactivator is a target for immune evasion in cancer
Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M. A., Lizee, G. A., & Kobayashi, K. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602069113 · Cited by 276
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
Self-citationTherapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273 · cited 6×
“A recent study used a CRISPR screening approach to identify factors that decouple the regulation of MHC-I and PD-L1 (99).”
MethodInfluentialWatson, N. F. S., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2006) · International Journal of Cancer · doi:10.1002/ijc.21303 · Cited by 254
Montesion, M., Murugesan, K., Jin, D. X., Sharaf, R., Sanchez, N., Guria, A., Minker, M., Li, G., Fisher, V., Sokol, E. S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0672 · Cited by 248
The role of cancer-derived microRNAs in cancer immune escape
Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00848-8 · Cited by 221 · cited 1×
“MiRNAs can affect various parts of the antigen presentation pathway, including TAP1/TAP2 and calreticulin (68, 70, 71).”
BackgroundSeliger, B. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01052-9 · Cited by 215
Gobin, S. J. P., Peijnenburg, A., Keijsers, V., & van den Elsen, P. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80348-9 · Cited by 210
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Hazini, A., Fisher, K., & Seymour, L. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002899 · Cited by 203
Nie, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1615 · Cited by 202
Watanabe, N., Sakakibara, J., Hovanessian, A. G., Taniguchi, T., & Fujita, T. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.16.4421 · Cited by 199
Mehta, A. M., Jordanova, E. S., Kenter, G. G., Ferrone, S., & Fleuren, G. J. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0362-8 · Cited by 192
Meric-Bernstam, F., Sandhu, S. K., Hamid, O., Spreafico, A., Kasper, S., Dummer, R., Shimizu, T., Steeghs, N., Lewis, N., Talluto, C. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2507 · Cited by 190 · cited 1×
“org 6 cell lung cancer and neuroblastoma (105, 106)Also, the EGFR family member, HER2, was shown to be inversely correlated with MHC-I expression in breast cancer and impairs T cell recognition of peptide: MHC-I complexes (107, 108).”
BackgroundGenomic structure and function in the MHC
Trowsdale, J. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90205-v · Cited by 188
Pharmacology and therapeutic potential of interferons
George, P. M., Badiger, R., Alazawi, W., Foster, G. R., & Mitchell, J. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.006 · Cited by 176
Cross-presentation of cell-associated antigens by MHC class I in dendritic cell subsets
Gutiérrez-Martínez, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00363 · Cited by 175
High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas
Cabrera, T., Collado, A., Fernandez, M. A., Ferron, A., Sancho, J., Ruiz‐Cabello, F., & Garrido, F. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb02274.x · Cited by 175
Vitale, M., Rezzani, R., Rodella, L. F., Zauli, G., Grigolato, P., Cadei, M., Hicklin, D. J., & Ferrone, S. (1998) · PubMed · Cited by 174
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Brea, E. J., Oh, C. Y., Manchado, E., Budhu, S., Gejman, R. S., Mo, G., Mondello, P., Han, J. E., Jarvis, C. A., Ulmert, D., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0177 · Cited by 173
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3283 · Cited by 169
The regulatory network behind MHC class I expression
Jongsma, M. L. M., Guarda, G., & Spaapen, R. M. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.005 · Cited by 161
Cordon‐Cardo, C., FUKS, Z. Y., Drobnjak, M., Moreno, C. S., Eisenbach, L., & Feldman, M. (1991) · PubMed · Cited by 158
Tseng, C.-W., Hung, C.-F., Alvarez, R. D., Trimble, C., Huh, W. K., Kim, D., Chuang, C.-M., Lin, C.-T., Tsai, Y.-C., He, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0037 · Cited by 158
Roelse, J., Grommé, M., Momburg, F., Hämmerling, G. J., & Neefjes, J. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.5.1591 · Cited by 153
Kalbasi, A. K., Tariveranmoshabad, M., Hakimi, K. N., Kremer, S. V., Campbell, K. M., Funes, J. M., Vega-Crespo, A., Parisi, G., Champhekar, A. S., Nguyen, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0152 · Cited by 144
Fonsatti, E., Nicolay, H. J. M., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., & Maio, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3091 · Cited by 139
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Fang, Y., Wang, L., Wan, C., Sun, Y., der Jeught, K. V., Zhou, Z., Dong, T., So, K. M., Yu, T., Li, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140837 · Cited by 137
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Chew, G.-L., Campbell, A. E., Neef, E. D., Sutliff, N. A., Shadle, S. C., Tapscott, S. J., & Bradley, R. K. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.011 · Cited by 135
Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients
Menon, A. G., Morreau, H., Tollenaar, R. A. �. �., Alphenaar, E. A., van Puijenbroek, M., Putter, H., Rhijn, C. M. J., van de Velde, C. J. �., Fleuren, G. J., & Kuppen, P. J. K. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000043124.75633.ed · Cited by 131
Moufarrij, S., Srivastava, A., Gomez, S., Hadley, M. M., Palmer, E., Austin, P. T., Chisholm, S., Diab, N., Roche, K. C., Yu, A. Y. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60409-4 · Cited by 126
High frequency of altered HLA class I phenotypes in invasive breast carcinomas
Cabrera, T., Fernandez, M. A., Sierra, À., Garrido, A., Herruzo, A., Escobedo, A., Fabra, À., & Garrido, F. (1996) · Human Immunology · doi:10.1016/0198-8859(96)00145-0 · Cited by 126
Maleno, I., López‐Nevot, M. Á., Cabrera, T., Jose, S., & Garrido, F. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0296-0 · Cited by 122
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
PROPPER, D. J., Chao, D., Braybrooke, J. P., Bahl, P., Thavasu, P., Balkwill, F. R., Turley, H., Dobbs, N. A., Gatter, K. C., Talbot, D. C., et al. (2003) · PubMed · Cited by 115
Gobin, S. J. P., Keijsers, V., van Zutphen, M., & van den Elsen, P. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2276 · Cited by 115
Kriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900475 · Cited by 114
Gobin, S. J. P., Keijsers, V., van Zutphen, M., & van den Elsen, P. J. (1998) · PubMed · Cited by 110
Chang, C., Hammer, J., Loh, J. E., Fodor, W. L., & Flavell, R. (1992) · Immunogenetics · doi:10.1007/bf00179793 · Cited by 109
Yan, Y., Zheng, L., Du, Q., Yan, B., & Geller, D. A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02586-9 · Cited by 109
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107
Siebenkäs, C., Chiappinelli, K. B., Guzzetta, A. A., Sharma, A. R., Jeschke, J., Vatapalli, R. J., Baylin, S. B., & Ahuja, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179501 · Cited by 107
Seliger, B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampé, R., & Huber, C. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<122::aid-immu122>3.0.co;2-f · Cited by 99
Lorenzi, S., Forloni, M., Cifaldi, L., Antonucci, C., Citti, A., Boldrini, R., Pezzullo, M., Castellano, A., Russo, V. E. A., van der Bruggen, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046928 · Cited by 98
Kaklamanis, L., Townsend, A., Doussis-Anagnostopoulou, I. A., Mortensen, N. J. M., Harris, A. L., & Gatter, K. C. (1994) · PubMed Central · Cited by 97
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Luo, N., Formisano, L., Ericsson, P. I. G., Sanchez, V. M., Dean, P. T., Opalenik, S. R., Sanders, M. E., Cook, R. S., Arteaga, C. L., Johnson, D. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438106 · Cited by 97
Self-citationHurkmans, D. P., Kuipers, M. E., Smit, J., van Marion, R., Mathijssen, R. H. J., Postmus, P. E., Hiemstra, P. S., Aerts, J. G. J. V., von der Thüsen, J. H., & van der Burg, S. H. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02506-x · Cited by 97
Mari, L., Hoefnagel, S. J. M., Zito, D., van de Meent, M., Endert, P. V., Calpe, S., Sancho‐Serra, M. D. C., Heemskerk, M. H. M., van Laarhoven, H. W. M., Hulshof, M. C. C. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.030 · Cited by 94
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer
Gurjao, C., Liu, D., Hofree, M., AlDubayan, S. H., Wakiro, I., Su, M.-J., Felt, K. D., Gjini, E., Brais, L. K., Rotem, A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0683 · Cited by 94
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
Castro, A., Öztürk, K., Pyke, R. M., Su, X., Zanetti, M., & Carter, H. K. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0544-1 · Cited by 94
Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA
Holland, C. J., Crean, R., Pentier, J. M., de Wet, B., Lloyd, A., Velupillai, S., Lissin, N. M., Lloyd, K. A., Blicher, T. H., Conroy, P. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130562 · Cited by 92
Seliger, B., Höhne, A., Knuth, A. K., Bernhard, H., Ehring, B., Tampé, R., & Huber, C. G. (1996) · PubMed · Cited by 91
Colangelo, T., Polcaro, G., Ziccardi, P., Pucci, B., Muccillo, L., Galgani, M., Fucci, A., Milone, M. R., Budillon, A., Santopaolo, M., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.28 · Cited by 89
Srivastava, R. M., Trivedi, S., Concha‐Benavente, F., Jie, H.-B., Wang, L., Seethala, R. R., Branstetter, B. F., Ferrone, S., & Ferris, R. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0053 · Cited by 83
TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors
Doorduijn, E. M., Sluijter, M., Querido, B. J., Oliveira, C. C., Achour, A., OSSENDORP, F. A., van der Burg, S. H., & van Hall, T. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83671 · Cited by 82
Iwai, T., Sugimoto, M., Wakita, D., Yorozu, K., Kurasawa, M., & Yamamoto, K. (2018) · Oncotarget · doi:10.18632/oncotarget.25830 · Cited by 82
Srivastava, P., Paluch, B. E., Matsuzaki, J., James, S. R., Collamat, G., Taverna, P., Karpf, A. R., & Griffiths, E. A. (2015) · Epigenetics · doi:10.1080/15592294.2015.1017198 · Cited by 81
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Inoue, M., Mimura, K., Izawa, S., Shiraishi, K., Inoue, A., Shiba, S., Watanabe, M., Maruyama, T., Kawaguchi, Y., Inoue, S., et al. (2012) · Oncoimmunology · doi:10.4161/onci.21056 · Cited by 80
Stratikos, E., Stamogiannos, A., Zervoudi, E., & Fruci, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00363 · Cited by 73
Mora‐García, M. D. L., Dueñas‐González, A., Hernández‐Montes, J., la Cruz-Hernández, E. N. D., Pérez‐Cárdenas, E., Weiss‐Steider, B., Santiago‐Osorio, E., Ortiz-Navarrete, V. F., Rosales, V. H., de León, D. F. C., et al. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-55 · Cited by 72
Improving cancer immunotherapy with DNA methyltransferase inhibitors
Saleh, M. H., Wang, L., & Goldberg, M. S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1776-3 · Cited by 71
Noncoding RNAs: the shot callers in tumor immune escape
Liu, L., Wang, Q., Qiu, Z., Kang, Y., Liu, J., Ning, S., Yin, Y., Pang, D., & Xu, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0194-y · Cited by 70
Shionoya, Y., Kanaseki, T., Miyamoto, S., Tokita, S., Hongo, A., Kikuchi, Y., Kochin, V., Watanabe, K., Horibe, R., Saijo, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1274476 · Cited by 68
Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma
Spel, L., Nieuwenhuis, J., Haarsma, R., Stickel, E., Bleijerveld, O. B., Altelaar, M. A. F., Boelens, J. J., Brummelkamp, T. R., Nierkens, S., & Boes, M. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0545 · Cited by 68
Zhao, Y. C., Cao, Y., Chen, Y., Wu, L., Hang, H., Jiang, C., & Zhou, X. (2021) · Immunology · doi:10.1111/imm.13384 · Cited by 67
Ye, Q., Shen, Y., Wang, X., Yang, J., Miao, F., Shen, C., & Zhang, J. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01390.x · Cited by 65
Segars, J. H., Nagata, T., Bours, V., Medin, J. A., Franzoso, G., Blanco, J. C. G., Drew, P. D., Becker, K. G., An, J., & Tang, T. L. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6157 · Cited by 63
Sun, T., Li, Y., Yang, W., Wu, H., Li, X., Huang, Y.-L., Zhou, Y., & Du, Z. (2019) · Journal of Cancer · doi:10.7150/jca.34471 · Cited by 61
MHC class I transactivator NLRC5 in host immunity, cancer and beyond
Cho, S., Vijayan, S., Yoo, J., Watanabe, T., Ouda, R., An, N., & Kobayashi, K. S. (2020) · Immunology · doi:10.1111/imm.13235 · Cited by 61
Shukla, A., Cloutier, M., Santharam, M. A., Ramanathan, S., & Ilangumaran, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041964 · Cited by 61
T cell recognition of HLA‐A2 restricted tumor antigens is impaired by the oncogene HER2
Mimura, K., Ando, T., Poschke, I., Mougiakakos, D., Johansson, C. C., Ichikawa, J., Okita, R., Nishimura, M., Handke, D., Krug, N., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25613 · Cited by 60
Calnexin is a novel sero-diagnostic marker for lung cancer
Kobayashi, M., Nagashio, R., Jiang, S., Saito, K., Tsuchiya, B., Ryuge, S., Katono, K., Nakashima, H., Fukuda, E., Goshima, N., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.015 · Cited by 57
The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity
Meissner, T. B., Li, A., Liu, Y.-J., Gagnon, É., & Kobayashi, K. S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.01.104 · Cited by 56
ER quality control in the biogenesis of MHC class I molecules
Chapman, D. C., & Williams, D. B. (2010) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.12.013 · Cited by 56
CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression
Downs, I., Vijayan, S., Sidiq, T., & Kobayashi, K. S. (2016) · BioFactors · doi:10.1002/biof.1285 · Cited by 55
Hirata, T., Yamamoto, H., Taniguchi, H., Horiuchi, S., Oki, M., Adachi, Y., Imai, K., & Shinomura, Y. (2007) · The Journal of Pathology · doi:10.1002/path.2142 · Cited by 44
Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
Garrido, G., Rabasa, A., Garrido, C., Chao, L., Garrido, F., Garcia-Lora, A. M., & Sánchez-Ramírez, B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00595 · Cited by 41
Park, H. S., Cho, U., Im, S. Y., Yoo, C. Y., Jung, J. H., Suh, Y. J., & Choi, H. J. (2018) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2018.10.11 · Cited by 41
Lazaridou, M., Gonschorek, E., Massa, C., Friedrich, M., Handke, D., Mueller, A., Jasinski‐Bergner, S., Dummer, R., Koelblinger, P., & Seliger, B. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774323 · Cited by 40
Farina, A. R., Masciulli, M. P., Tacconelli, A., Cappabianca, L. A., Santis, G. D., Gulino, A., & Mackay, A. R. (2002) · PubMed · Cited by 38
Roerden, M., Nelde, A., Heitmann, J. S., Klein, R., Rammensee, H., Bethge, W. A., & Walz, J. S. (2020) · Cancers · doi:10.3390/cancers12071835 · Cited by 38
NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy
Yoshihama, S., Cho, S., Yeung, J., Pan, X., Lizee, G. A., Konganti, K., Johnson, V. E., & Kobayashi, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82729-9 · Cited by 37
Campo, A. B., Carretero, J., Muñoz, J. A., Zinchenko, S. P., Ruiz‐Cabello, F., González‐Aseguinolaza, G., Garrido, F., & Aptsiauri, N. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.32 · Cited by 35
Lulli, D., Carbone, M. L., & Pastore, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102227 · Cited by 34
Oliveira, C. C., Querido, B. J., Sluijter, M., Derbinski, J., van der Burg, S. H., & van Hall, T. (2011) · European Journal of Immunology · doi:10.1002/eji.201141836 · Cited by 33
Hemmerle, T., & Neri, D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0182 · Cited by 33
Proteomic Analysis of Proteins Related to Prognosis of Lung Adenocarcinoma
Okayama, A., Miyagi, Y., Oshita, F., Nishi, M., Nakamura, Y., Nagashima, Y., Akimoto, K., Ryo, A., & Hirano, H. (2014) · Journal of Proteome Research · doi:10.1021/pr4012969 · Cited by 33
Franklin, D. A., James, J. L., Axelrod, M. L., & Balko, J. M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.109 · Cited by 30
Self-citationBernal, M., García-Alcalde, F., Concha, Á., Cano, C., Blanco, A. J., Garrido, F., & Ruiz‐Cabello, F. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1147-7 · Cited by 29
Messaoudene, M., Mourikis, T. P., Michels, J., Fu, Y., Bonvalet, M., Lacroix‐Triki, M., Routy, B., Fluckiger, A., Rusakiewicz, S., Roberti, M. P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz112 · Cited by 28
Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I–deficient breast cancer cells
Zhao, M., Sun, Y., Jiang, X., Liu, L., Liu, L., & Sun, L. (2019) · Immunologic Research · doi:10.1007/s12026-019-09111-w · Cited by 26
SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression
Alam, A., Taye, N., Patel, S., Thube, M. M., Mullick, J., Shah, V. K., Pant, R., Roychowdhury, T., Banerjee, N., Chatterjee, S., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.07.002 · Cited by 16
Lobashevsky, A. L., Krueger-Sersen, M., Britton, R., Littrell, C. A., Singh, S., Cui, C., Kashi, Z., Martin, R., Breman, A. M., Vance, G. H., et al. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.02.009 · Cited by 14
Yu, S., Zhao, Z., Chen, L., Gu, T., Yu, H., Tang, H., Wang, Q., & Wu, Y. (2020) · Immunotherapy · doi:10.2217/imt-2020-0173 · Cited by 10
Cited by
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 460
The paths and challenges of “off-the-shelf” CAR-T cell therapy: an overview of clinical trials
Moradi, V., Omidkhoda, A., & Ahmadbeigi, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115888 · Cited by 80
Metadata
- Authors
- Taylor, B. C., & Balko, J. M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-28
- Volume
- 13
- Pages
- 844866-844866
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4214606145
- Cited by
- 298
- References
- 125
- FWCI
- 21.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.